S1046
Clinical – Sarcoma, skin cancer, malignant melanoma
ESTRO 2026
specific. Conclusion:
comprising 14953 patients treated between 1955-2022 for 16752 lesions: 12064 basal cell carcinomas (BCC), 3525 cutaneous squamous cell carcinomas (cSCC), 639 other, and 524 not specified.
Despite multiple studies assessing cosmesis as an outcome following radiotherapy, there are variations in assessment methodologies, rendering comparisons impractical and unreliable. The conclusions from this systematic review aid development of robust KC- specific cosmesis assessment tools to enable accurate outcome-measure comparisons between treatment modalities. References: Kennedy SF., et al. Quality of life issues faced by patients with keratinocyte cancer: A systematic review. EJC 2024 Keywords: Cosmesis, radiation, systematic Postoperative Radiotherapy for Extremity Soft Tissue Sarcoma: Minimal Late Toxicity and Preserved Functional Outcomes Youngju Song 1 , Yeon Joo Kim 1 , Jong Seok Lee 2 , Wanlim Kim 2 , Jin-Hee Ahn 3 , Jeong Eun Kim 3 , Hye Won Chung 4 , Si Yeol Song 1 1 Department of radiation oncology, Asan medical center, university of Ulsan college of medicine, Seoul, Korea, Republic of. 2 Department of orthopedic surgery, Asan medical center, university of Ulsan college of medicine, Seoul, Korea, Republic of. 3 Department of oncology, Asan medical center, university of Ulsan college of medicine, Seoul, Korea, Republic of. 4 Department of radiology, Asan medical center, university of Ulsan college of medicine, Seoul, Korea, Republic of Purpose/Objective: While postoperative radiotherapy (RT) for extremity soft tissue sarcoma (E-STS) is often favored due to lower rates of late toxicity, our institution has Digital Poster 3598 historically adopted a postoperative RT strategy. This study aimed to evaluate the safety profile and patient- reported functional outcomes following postoperative RT. Material/Methods: We retrospectively analyzed 215 patients with E-STS treated with postoperative RT between 2015 and 2024. The primary endpoint was late treatment-related toxicity; secondary endpoints included acute toxicity, wound complications, patient-reported quality-of-life (MSTS score), local recurrence-free survival (LRFS), disease-free survival (DFS), and overall survival (OS). Toxicities were graded using CTCAE v5.0. Results: Most tumors were deep-seated (88.8%) and originated from the lower extremities (76.7%). Free flap closure was required in 33.5% of the cases, and 30.7%
Most studies were retrospective (57; 78%) with six prospective non-randomised (8%), and one randomised controlled trial (1%). Two (2%), 26 (37%), 15 (21%), and 15 (21%) records employed 2, 3, 4, and 6 gradings of cosmesis; 15 (21%) records did not specify cosmesis grade. Half of the tools reported pigmentation (56%), telangiectasia (52%), and fibrosis (52%) among cosmesis items, along with atrophy, deformity, and epilation at 40%, 37%, and 25%, respectively. Persons assessing cosmesis were specified as clinicians in 34 records (47%), patients in 7 records (10%), and both in four (5%). Acute (<90d) cosmesis was reported by 13 records, late (>90d) in 36 records, with 30/36 late assessments reporting cosmesis beyond 12 months; 36 (49%) did not specify timeframe of assessment.
Overall, the cosmesis scales reporting were graded as level 1 in 28 reports, level 2 in 19 reports, and 26 reports as level 3. Six cosmesis scales were externally referenced, including two scales that were not KC-
Made with FlippingBook - Share PDF online